Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Quetiapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 4/20 | 0.85 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.85 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.85 |
| ▸ | DRD3 | P35462 | 3/20 | 0.85 |
| ▸ | DRD4 | P21917 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.85 |
| ▸ | HTR1A | P08908 | 2/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.85 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.85 |
| ▸ | DRD1 | P21728 | 2/20 | 0.85 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.85 |
| ▸ | HRH1 | P35367 | 2/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quetiapine SCHEMBL29487500 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL122596 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL31678628 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL4962023 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41336 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL30990390 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5325208 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL678457 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL41338 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 | |
| Quetiapine SCHEMBL5070765 | 1.00 | KDM4E (1.00) | KDM4EMEN1MAPK1KMT2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250268823-A1 | Aqueous Quetiapine Solutions | RELIIS LTD. (AU) | 2025-08-28 | — | — | US | claimed |
| WO-2023201390-A1 | AQUEOUS QUETIAPINE SOLUTIONS | Reliis Ltd (AU) | 2023-10-26 | — | — | WO | claimed |
| CN-105061359-B | Refining method of quetiapine hemifumarate | 浙江华海药业股份有限公司 | 2021-01-19 | — | — | CN | claimed |
| EP-2262486-B1 | QUETIAPINE COMPOSITION | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2013-01-02 | — | — | EP | claimed |
| WO-2011132008-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION | EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság (HU) | 2011-10-27 | — | — | WO | claimed |
| US-8044039-B2 | Quetiapine hemifumarate purification by crystallization | FERMION OY (FI) | 2011-10-25 | — | — | US | claimed |
| US-8044038-B2 | Crystallization process of quetiapine hemifumarate | FERMION OY (FI) | 2011-10-25 | — | — | US | claimed |
| EP-2355804-A1 | QUETIAPINE COMPOSITION | KRKA (SI) | 2011-08-17 | — | — | EP | claimed |
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | claimed |
| EP-2262486-A1 | QUETIAPINE COMPOSITION | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2010-12-22 | — | — | EP | claimed |
| CN-1777594-A | Synthesis of quetiapine and pharmaceutically acceptable salts thereof | TEVA PHARMA (IL) | 2006-05-24 | — | — | CN | claimed |
| WO-2006035293-A1 | POLYMORPHIC FORMS OF QUETIAPINE HEMIFUMARATE | RANBAXY LABORATORIES LIMITED (IN) | 2006-04-06 | — | — | WO | claimed |
| US-20050158383-A1 | Quetiapine formulations | ACTAVIS GROUP PTC EHF | 2005-07-21 | — | — | US | claimed |
| WO-2005041935-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING QUETIAPINE | ALPHARMA, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| EP-1495008-A1 | SYNTHESIS OF QUETIAPINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Teva Pharmaceutical Industries Limited (IL) | 2005-01-12 | — | — | EP | claimed |
| EP-1482945-A1 | CRYSTALLINE FORMS OF QUETIAPINE HEMIFUMARATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-08 | — | — | EP | claimed |
| US-20040220400-A1 | Synthesis of quetiapine and pharmaceutically acceptable salts thereof | TEVA PHARMACEUTICALS USA, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2004076431-A1 | SYNTHESIS OF QUETIAPINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-09-10 | — | — | WO | claimed |
| US-20030216376-A1 | Crystalline forms of quetiapine hemifumarate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-20 | — | — | US | claimed |
| WO-2003080065-A1 | CRYSTALLINE FORMS OF QUETIAPINE HEMIFUMARATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-10-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220400-A1 | Synthesis of quetiapine and pharmaceutically acceptable salts thereof | SLC6A4, SLC6A3, SLC6A11 | DRD2 73/4885HTR2A 86/4885HTR2C 184/4885 |
| US-20030216376-A1 | Crystalline forms of quetiapine hemifumarate | CYP4F3, FH, SDHA | DRD2 913/4885HTR2A 511/4885HTR2C 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.